Welcome to LookChem.com Sign In|Join Free

Hebei Mojin Biotechnology Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
5th
years
Home>>Products>>Mavacamten 1642288-47-8

Product Certification&
Enterprise Certification

More Detail

Hebei Mojin Biotechnology Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Mr.xing

Tel: 13231137666

Ms.bella gao

Tel: 15028179902

Ms.june wang

Tel: 13383610321

Ms.Angelia

Tel: +86 13288715578

Ms.emma

Tel: 13288715308

Ms.betty

Tel: 15028179772

Ms.may

Tel: 13315458396

Ms.april

Tel: 15103291926

Mobile: 13231137666

Tel: 13231137666

Fax:

URL: http://www.hbmojin.com

Province/state: Hebei

City: shijiazhuang

Street: room 1401,A building,Enjoy city,shijiazhuang city,hebei province,China

MaxCard:


qq Contact Suppliers

Mavacamten 1642288-47-8

CAS NO.1642288-47-8

  • FOB Price: USD: 25.00-25.00 /Metric Ton Get Latest Price
  • Min.Order: 1 Kilogram
  • Payment Terms: T/T
  • Available Specifications:

    comestic(1-22)Metric Toncomestic(1-22)Metric Ton

Contact Supplier

Product Details

Keywords

  • CAS 1642288-47-8
  • Mavacamten
  • Hi-Q(high quality)

Quick Details

  • ProName: Mavacamten 1642288-47-8
  • CasNo: 1642288-47-8
  • Molecular Formula: C15H19N3O2
  • Appearance: White solid
  • Application: MYK-461 is a drug used to treat obstru...
  • DeliveryTime: within 2-3 day
  • PackAge: carton boc
  • Port: tianjin/qingdao/shanghai
  • ProductionCapacity: 1000000 Kilogram/Month
  • Purity: 99%
  • Storage: cool and dry
  • Transportation: by air or by sea or by express
  • LimitNum: 1 Kilogram
  • 1: 100

Superiority

MYK-461 is a drug used to treat obstructive hypertrophic cardiomyopathy as a cardiac myosin inhibitor. 

Mavacamten is used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy.

It is used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Mavacamten(MYK-461)is a first-in-class allosteric inhibitor of cardiac myosin that promises to provide clinicians with targeted therapy for these patients.

It is a mechanistically novel small molecule that acts on the sarcolemma to specifically inhibit contractility and has been proposed as a treatment for HCM.

Details

Product  information

CAS: 1642288-47-8
MF: C15H19N3O2
MW: 273.33
density  1.19±0.1 g/cm3(Predicted)
solubility  insoluble in H2O; ≥11.32 mg/mL in EtOH with ultrasonic; ≥13.65 mg/mL in DMSO
form  solid
pka 8.83±0.40(Predicted)
InChI InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1

Company Profile

Why choose us

Our servies